Loading...

Charles Redfern

TitleAssociate Physician
InstitutionUniversity of California San Diego
DepartmentFamily Medicine and Public Health
Address200 W. Arbor Drive #8204
San Diego CA 92103
Phone619-543-6770
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    G PROTEIN SIGNALING AND TISSUE PROLIFERATION
    NIH/NCI K08CA071779Jul 5, 1996 - Jun 30, 2001
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 Jun 04. PMID: 29880291.
      View in: PubMed
    2. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern C, Shore ND. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3862-9. PMID: 25925891.
      View in: PubMed
    3. Eppler S, Gordon MS, Redfern C, Trudeau C, Xu N, Han K, Lum BL. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anticancer Drugs. 2015 Apr; 26(4):448-55. PMID: 25643049.
      View in: PubMed
    4. Xu N, Redfern C, Gordon M, Eppler S, Lum BL, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1251-60. PMID: 25344761; PMCID: PMC4236615.
      View in: PubMed, PubMed Central
    5. Boasberg PD, Redfern C, Daniels GA, Bodkin D, Garrett CR, Ricart AD. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):547-52. PMID: 21516509.
      View in: PubMed
    6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern C, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22. PMID: 20818862.
      View in: PubMed
    7. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother. 2010 Feb-Mar; 33(2):178-84. PMID: 20145546.
      View in: PubMed
    8. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern C, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb 20; 25(6):669-74. PMID: 17308271.
      View in: PubMed
    9. Small EJ, Schellhammer PF, Higano CS, Redfern C, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 01; 24(19):3089-94. PMID: 16809734.
      View in: PubMed
    10. Redfern C, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006 Jul 01; 24(19):3107-12. PMID: 16754937.
      View in: PubMed
    11. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother. 2004 May-Jun; 27(3):232-9. PMID: 15076141.
      View in: PubMed
    12. Scearce-Levie K, Coward P, Redfern C, Conklin BR. Tools for dissecting signaling pathways in vivo: receptors activated solely by synthetic ligands. Methods Enzymol. 2002; 343:232-48. PMID: 11665570.
      View in: PubMed
    Charles's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (103) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (4) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑